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A B S T R A C T
Morphine is an opioid alkaloid commonly used in clinical practice for its analgesic properties. The phenolic
hydroxyl group of that phenanthrene derivative is pivotal for binding to opioid receptors but it may also be
responsible for the antioxidant behavior of morphine reported in several in vitro experiments. In this study, we
assessed the effect of morphine on myeloperoxidase (MPO), a hemic enzyme from azurophilic granules of
polymorphonuclear neutrophils involved in the production of cytotoxic and microbicidal reactive oxidants
during inflammatory response. Specific immunological extraction followed by enzyme detection (SIEFED) and
molecular modeling (docking) were performed to study the potential anti-catalytic action of morphine on MPO
in comparison with the inhibitory effects of reference antioxidant molecules quercetin, gallic acid and ascorbic
acid. The reducing action of morphine on the MPO peroxidase cycle has been investigated using electron
paramagnetic resonance (EPR) and UV-visible absorption spectroscopy. Morphine acted as a reducing substrate
in the peroxidase cycle of MPO and therefore protected the enzyme against the suicide action of its natural
substrate, hydrogen peroxide. The SIEFED experiments associated with the docking study, further demonstrated
a lack of strong and sustained anti-catalytic activity of morphine. In summary, from the results of this study, it
appears that morphine acts as a weak and reversible inhibitor of MPO that may nonetheless contribute to im-
munomodulatory and antioxidant effects of this opioid analgesic in vivo.
1. Introduction
Inflammation is a complex physiological phenomenon involving
cellular, enzymatic and chemical mechanisms to remove damaged host
structures, prevent invasion by various infectious agents or tumor cells
and prepare for future tissue repair and regeneration. During this
phenomenon, polymorphonuclear leukocytes (PMNs) play an important
role by producing reactive oxygen species (ROS) like superoxide anion,
hydroxyl radical or singlet oxygen. PMNs also release myeloperoxidase
(MPO), a pro-oxidant hemic enzyme belonging to their intricate oxi-
dative system. [1–5] MPO is a peroxidase, composed of two symme-
trical hemi-enzymes, each owns a heme constituted of a porphyrin and
an iron atom in the ferric state. This enzyme has two main activities:
chlorination and peroxidase, closely related to the production of ROS.
As a peroxidase, MPO catalyzes the oxidation of substrates, acting as
electron donors, via hydrogen peroxide, its natural substrate [6–9].
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During the first step, the resting state of the enzyme is oxidized to its
oxoferryl π-cation radical state, called compound I. In the presence of
chloride anion (Cl−), this compound takes place in the chlorination
cycle, yielding hypochlorous acid (HOCl), a strong oxidant [10]. For the
peroxidase cycle, compound I is reduced to a second non-radical ox-
oferryl intermediate, compound II. The final step of the cycle is the
reduction of compound II to the native state (Fig. 1). The peroxidase
cycle of MPO catalyzes the oxidation of various substrates like nitrite,
tyrosine, ascorbate, … The radicals formed can then oxidize biological
molecules such as phospholipids forming the plasma membrane of host
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cells and pathogen agents [8,11–14].
Although this oxidative pathway is highly effective in clearing da-
maged host cells and invading pathogens, the oxidant species lack se-
lectivity and may paradoxically induce oxidative injuries to healthy
tissues. Our previous works demonstrated that MPO played a patho-
physiological role in various inflammatory diseases in animal [15,16].
In human, MPO is involved in tissue damages associated with
ischaemia-reperfusion and systemic inflammatory response during
sepsis, trauma and shock. [17] Therefore, pharmacological inhibition of
MPO may represent an attractive therapeutic opportunity in various
inflammatory diseases associated with excessive or protracted activa-
tion of PMNs [18].
While researches focused on the design of new molecules [18–23],
presenting the best structure to be effective and specific MPO inhibitors,
an alternative approach has consisted in examining the anti-MPO ac-
tivity of a clinically-approved molecule, morphine, at the light of most
recent physico-chemical investigation means in order to outline its
immunomodulatory and antioxidant potential.
Morphine is an opioid phenanthrene alkaloid and ranges among the
most commonly used analgesics to treat moderate to severe pain in
clinical practice. The phenolic hydroxyl group of morphine is pivotal
for its binding to opioid receptors and analgesic properties (Fig. 2).
This specific group also confers to morphine a phenol-like behavior
during its metabolism oxidation by cytochrome P450, especially in liver
microsomes [24–27]. The degradation in its derivatives, normorphine,
hydroxymorphine, codeine, via the interaction with P450 active site,
may suggest the ability of morphine to present an antioxidant behavior
towards the peroxidase activity. Morphine has shown to manifest an
antioxidant action, such as ROS scavenging effects, free radicals re-
duction or metal chelation [28]. This antioxidant activity has also been
proven in vitro [29,30]. In addition, it has also been demonstrated that
morphine inhibits the ROS production by inflammatory cells such as
PMNs [31]. Moreover, preliminary results have recently shown the
ability of morphine to inhibit MPO degranulation from stimulated
human PMNs and to interfere with both peroxidase and chlorination
activities of the MPO enzyme as reported Minguet et al., in a personal
communication [32].
Considering the important involvement of MPO in the inflammatory
response, we sought to further evaluate the inhibitory activity of mor-
phine on MPO and outline the mechanisms of morphine-MPO interac-
tions. The aim of this study was to determine if morphine can belong to
reversible inhibitors of the enzyme in order to precise its antioxidant
and anti-inflammatory potential. The antioxidant action of morphine
has been compared to the one of antioxidant reference molecules,
having already demonstrated their ability to interact with MPO (quer-
cetin, gallic acid and ascorbic acid (Fig. 2)) [14,33–37]. First, the po-
tential anti-catalytic property of morphine was tested on MPO with
SIEFED, Specific Immunological Extraction Followed by Enzyme De-
tection, an immunological technique able to measure specifically the
MPO activity after exposure to potential inhibitors [37,38]. The mole-
cular docking between morphine and MPO in comparison with the
selected reference molecules was performed to complete the anti-cat-
alytic experiments and obtain key information about the kind of in-
teraction between the tested ligands and the enzyme [18,20,39,40].
The influence of morphine on MPO peroxidase cycle intermediates was
investigated thanks to the UV–visible absorption. UV–visible spectro-
scopy is an effective technique to study the direct action of a substrate
on a peroxidase enzyme [21,41–44]. Likewise, the ABTS model [45,46]
was performed to study the reducing action of morphine on the MPO
peroxidase cycle. As the peroxidase activity undergoes radical pro-
cesses, it was interesting to monitor the reducing action of morphine
using electron paramagnetic resonance technique (EPR) in the presence
of ABTS as co-substrate.
2. Materials and methods
2.1. Materials
Morphine (under chlorhydrate form) was purchased from Sterop
group (Brussels, Belgium). From the stock solution (10mg/ml), the
diluted solutions were freshly prepared in distilled water to obtain a
final concentration range from 10−6 M to 5 10−4 M. The use of con-
centrations, higher than clinic ones, from 10−6 M and below [47,48],
allows to further investigated the mechanism of interaction between
morphine and MPO. The stock solution of MPO (Merck Millipore,
Leuven, Belgium) was prepared in phosphate buffer (50mM) pH 7.4.
Hydrogen peroxide was purchased from Merck Millipore and ABTS
(2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic) acid) was pur-
chased from Amresco (Solon, USA). Different reference inhibitors were
used in this study: quercetin (Fluka AG Chemische Fabrik, Saint-Louis,
Fig. 1. Peroxidase and chlorination cycles of MPO.
Fig. 2. Chemical structures of the antioxidant molecules studied.
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USA), gallic acid and ascorbic acid (UCB, Brussels, Belgium). Gallic acid
and ascorbic acid were diluted in distilled water, whereas quercetin was
diluted in DMSO. For the SIEFED experiment, sodium nitrite was from
Sigma Aldrich (St-Louis, USA) and Amplex red from Molecular Probes
(Invitrogen, Merelbeke, Belgium).
2.2. EPR studies and UV–visible absorption
All the EPR spectra were recorded on a Bruker ER082C spectrometer
(EMX-micro, Karlsruhe, Germany) at room temperature with a 100 kHz
modulation frequency (9.78 GHz microwave frequency, 18mW micro-
wave power). The micro-capillaries containing the samples were placed
in an EPR quartz cell, to be inserted in the cavity. Absorption spectra
were recorded with a multichannel (1024-element diode array) Agilent
8453 spectrophotometer (Hewlett-Packard, Waldbronn, Germany) and
the samples were placed in a quartz cell, with an optical path 1 cm. The
concentration of MPO has been determined by measuring the absor-
bance of the native enzyme Soret band at 430 nm
(ε430nm= 91,000M−1 cm−1 [14]).
2.3. SIEFED assay
Solutions containing 50 ng/ml of MPO and selected inhibitors at
several concentrations were incubated for 10min at 37 °C, in PBS
buffer. One hundred microliters of each solution were placed in a 96-
wells microtiter plate (Combiplate 8 EB), from Thermo Scientific
(Breda, Netherlands), coated with rabbit anti-human MPO polyclonal
antibodies (CORD, Belgium). Solvent controls were performed by re-
placing the inhibitors by their solvent (water or DMSO). The plate was
incubated for 2 h at 37 °C. The washing step consisted of four washes of
the wells with a PBS solution containing 0.1% Tween 20. The perox-
idase cycle of MPO was initiated by adding in each well: 10 μl of sodium
nitrite (50mM) and 100 μl of a solution containing 40 μM Amplex red
and 10 μM of H2O2in phosphate buffer (50mM) at pH=7.5.
The solutions, not used for the coated plate, were used to make an
ELISA direct analysis. One hundred microliters of the solution were
added in the 96-wells plate, free of anti-human MPO antibodies. The
peroxidase cycle of MPO was initiated in the same way than for SIEFED
experiment without incubation and washing steps.
A spectrometer Fluoroskan Ascent (Thermo Scientific, Waltham,
USA) was used to measure the fluorescence signal of oxidized Amplex
red at 590 nm (excitation wavelength 544 nm), for 30min.
The statistical test used on the results is ANOVA: one way ANOVA
with Dunnett post test. The results for the tested compounds were all
compared to their respective control (distilled water or DMSO). A P
value of< 0.05 was considered significant.
2.4. Docking
Molecular docking of the MPO-inhibitors complexes was performed
with the program Gold [49]. The force-fields scoring function used was
Goldscore. In the procedure, the enzyme structure was extracted from
the PDB crystal structure 4C1M and energy minimized with the pro-
gram Yasara [50], after the suppression of the co-crystallized inhibitor
HX1. The oxidation state of the two heme iron ions has been modified
to obtain the Fe3+ state. A 15 Å cubic zone centered on the iron has
been defined to limit the positioning of the inhibitor. The selected
docking parameters allowed to reproduce the crystallographic structure
of the MPO-HX1 complex. The visualization of the docking solutions
was done with Pymol [51] and the determination of the binding be-
tween the inhibitors and MPO has been realized with LigPlot [52].
Yasara was used to minimize the complexes structures, to perform a
molecular dynamics simulation and to evaluate the complexes binding-
energy.
3. Results and discussion
3.1. SIEFED experiment
The SIEFED and the direct analysis (see Materials and methods)
allow to investigate the interaction between MPO and a potential in-
hibitor. Whereas, the SIEFED indicates the ability of a ligand to bind to
the enzyme active site and the reversibility of this interaction, the direct
analysis informs about a global enzyme-ligand interaction, without
being able to distinguish between the stoichiometric reducing action on
the MPO peroxidase cycle and the anti-catalytic one. These two tech-
niques are therefore complementary. Indeed, the absence of MPO ac-
tivity inhibition measured by SIEFED does not mean the absence of
interactions between the ligand and the enzyme.
The results of the direct analysis are summarized in Fig. 3. This
experiment allows to study simultaneously two inhibitors action path-
ways on MPO: the anti-catalytic and the stoichiometric reducing actions
on the peroxidase cycle. Indeed, without the washing step, the tested
molecules could compete or interfere with the revelation substrates
(Amplex Red, nitrite) used to measure MPO activity.
Quercetin and gallic acid presented a total inhibition on the MPO
activity, at concentrations ranging from 10−5 M to 10−4 M. Their in-
hibition action at the lowest concentration of 10−6 M, decreased to
around 40%. These results demonstrate the strong interaction between
these two polyphenols and MPO. In contrast, morphine exhibited a
concentration dependent inhibitory action, with>60% inhibition al-
ready at the concentration 10−5 M. The use of high concentrations, but
not relevant in a clinical use, allowed to investigate the interaction
mechanism between morphine and MPO. Indeed, the direct assay
proves the capacity of morphine to compete with substrates to get close
to and interact with the active site. According to the dose-dependent
behavior observed, a clinic relevant concentration of 3.5 10−6 M (1 μg/
ml) should present an MPO activity inhibitory action. Ascorbic acid
inhibited 97% of the MPO activity at concentrations ranging from
10−5 M to 10−4 M, but presented a weaker inhibitory action (9%) than
quercetin and gallic acid at 10−6 M.
The introduction of a washing step in the SIEFED protocol allows to
study the potential binding of the ligand to the MPO structure and
therefore to evaluate the reversibility of the inhibitor interaction. The
SIEFED assay performed in the presence of solvent controls (DMSO and
H2O) showed only a 10% decrease of the MPO activity for DMSO and
no significant effect for water versus the enzyme control (without
Fig. 3. Effect of gallic acid, quercetin, ascorbic acid and morphine on MPO
activity. The percentages of inhibition of MPO activity for each molecule were
calculated versus their respective solvent control. *P < 0.05 versus respective
control was found statistically significant, otherwise NS: not significant. Data
are given as mean ± SD (n≤ 6).
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solvent or tested molecules) (Fig. 4). In contrast, the two polyphenols,
gallic acid and quercetin, exhibited a total inhibition of the MPO ac-
tivity at concentrations equal or higher to 10−5 M. However, when used
at intermediate concentrations (2.5 10−5 M, 5 10−5 M and 7.5
10−5 M), both polyphenols do not either showed any dose-dependent
action (Data not shown). In contrast, the assay done in the presence of
morphine, at concentrations ranging from 10−6 M to 10−4 M, did not
induce any inhibition on the MPO activity. While ascorbic acid ex-
hibited a concentration dependent inhibitory action and reached quite a
complete inhibition (92%) at 10−4 M (Fig. 4).
Our SIEFED results clearly suggest the lack of an anti-catalytic ac-
tion of morphine, or at least, the weakness of the bonds, potentially
formed between morphine and MPO during incubation and broken
during the washing step. The results shown on Fig. 4 indicate the total
elimination of morphine in solution during the washing step, in our
experimental conditions, illustrating the reversibility of its inhibitory
action towards MPO. In comparison to morphine, it appears that
polyphenols, like quercetin and gallic acid, form stronger bonds with
MPO and its active site.
Furthermore, when comparing the 3D structure and the steric hin-
drance of morphine to that of small size molecules like gallic acid or
molecules with planar structure like quercetin, we can state that the
insertion of morphine in the enzyme catalytic pocket is difficult like-
wise the formation of bonds with important amino acids. The weak
insertion probability may explain the lack of MPO activity inhibition by
morphine, at all the concentrations tested.
Gallic acid and quercetin presented a strong anti-catalytic action,
event at lower concentration of 10−6 M. These results are in agreement
with previous SIEFED and docking studies. [37,53] The authors show
that the small size of gallic acid, the planarity and the flexibility of
quercetin, and the presence of hydroxyl groups, especially the presence
of a pyrogallol group in gallic acid, support the simple entry of these
molecules inside the MPO active site and their strong fixation, resisting
to the washing step. However, the stronger inhibitory action observed
at the concentration of 10−6 M with the direct analysis, around 40% in
comparison to almost 20% for the SIEFED, suggest that the inhibitory
action of these molecules can be explain mainly by their binding to the
active site and secondly by a competition as reducing substrates with
the revelation substrates.
In the case of ascorbic acid, a dose-dependent action on the MPO
activity was observed, with an inhibitory activity of 92% at 10−4 M.
Nevertheless, the anti-catalytic action is less important than those of
polyphenols. As for morphine, the main MPO inhibition pathway of
ascorbic acid is a reducing action on the peroxidase cycle. This activity
goes together with the low anti-catalytic activity, to almost totally in-
hibit the MPO activity, at concentrations superior to 10−6 M, in the
direct analysis.
3.2. Docking
Docking simulations have been realized to determine the capacity of
the four molecules analyzed by SIEFED (morphine, quercetin, gallic
acid, ascorbic acid), to enter the active site of MPO, and to investigate
their binding mode with amino acids near the heme cavity. The dif-
ferent inhibitors were docked in the heme pocket using the GOLD
program. Five runs have been performed for each inhibitor, with the
aim to determine the most frequent solutions and ensure their re-
producibility.
The docking of quercetin into the MPO active site gave two plau-
sible solutions (Fig. 5). The first one is similar to that reported by Shiba
et al. [53], obtained with FlexX, where the B-ring is stacked parallel to
the heme, near the D pyrrole ring.
Quercetin forms hydrogen bonds with two amino acids. Among
them, His 95 is essential to trigger the MPO peroxidase cycle, by linking
with H2O2. The bond between quercetin and this amino acid residue
Fig. 4. Effect of gallic acid, quercetin, ascorbic acid and morphine on MPO
activity measured by the SIEFED method. The percentages of inhibition of MPO
activity for each molecules were calculated versus their respective solvent
control. *P < 0.05 versus respective control was found statistically significant,
otherwise NS: not significant. Data are given as mean ± SD (n≤ 6).
Fig. 5. The two most plausible docking solutions of the quercetin-MPO complex
by GOLD. The yellow dashed lines represent the hydrogen bond between the
ligand and MPO residue. Selected distances (in Angström) are given on the
scheme.
P. Nyssen et al. BBA - General Subjects 1862 (2018) 2236–2244
2239
(Fig. 5A) explains the anti-catalytic action of the inhibitor as observed
by SIEFED.
The second solution (Fig. 5B) places the linked aromatic cycles of
the molecule above and parallel to the heme plane. The B-ring is or-
iented between the two propanoic acid side chains of the porphyrin.
This solution is the most frequent one obtained with Gold in our
modeling conditions. The difference between our results and those re-
ported by Shiba et al. [53] can be explained by the use of different
scoring function and a different input enzyme structure.
The comparison of our two docking solutions with the SIEFED re-
sults, is in favor of the solution A. Indeed, in solution B, quercetin binds
with two flexible cavity residues, in particular Thr 100. Being posi-
tioned at the entrance of the heme cavity, its mobility induces a weaker
bond with the inhibitor. Indeed, the comparison of the two solutions A
and B binding energy (data not shown), confirms the higher stability of
the complex A.
As for quercetin, the small number of different complex solutions
between gallic acid and MPO, provided by GOLD, informs about the
good stability of the complex. Indeed, it shows the ease of the docking
algorithm to position the ligand to maximize the interactions with
amino acids near the heme. The limited number of solutions indicates
the good reliability of the docking results. In the case of gallic acid, a
solution stands out (Fig. 6), where the carboxyl group is above the heme
center and is linked to both His 95 and Gln 91 residues via a hydrogen
bond. The ring is above the D pyrrole ring and slightly leaning com-
pared to the heme plane, placing a hydroxyl group between the two
propanoic acid side chains of the heme. The association of the bond
with the iron ion and His 95 is in agreement with the high anti-catalytic
activity of gallic acid.
The docking approach gave a restricted number of solutions for the
complex between morphine and MPO. The most frequent solution
places morphine in front of the heme (Fig. 7). In this position, morphine
is far from the heme and specific amino acids like His 95 contrary to
quercetin or gallic acid. The morphine 3D structure makes its orienta-
tion difficult in relation to the heme plane. No morphine cycle is par-
allel to the heme plane and the structure is tilted in a way to place the
hydroxyl function of the phenol ring between the two heme propanoic
acid side chains. The binding of morphine with two flexible residues
(Fig. 7) placed away from the heme and to one of the flexible heme
chain explains the low binding of the molecule with the enzyme, which
does not resist to the SIEFED washing step. Indeed, the evaluation of the
morphine-MPO complex binding energy shows the very low binding
ability of morphine in comparison to quercetin and gallic acid.
In contrast to the other tested ligands, the GOLD program gave a
large number of possible solutions for the structure of the ascorbic acid-
MPO complex. This illustrates the difficulty to define a unique sa-
tisfying solution and therefore the complexity to place the ascorbic acid
molecule in an energy optimum way inside the MPO cavity. Fig.8 shows
the most plausible solution obtained with our parameters. The posi-
tioning of the alkyl chain to the five atoms cycle does not allow the
molecule to be sufficiently close to the heme to form a bond with His 95
and to place the cycle parallel to the heme plane. The molecule is in-
serted between the two heme propanoic acid side chains which allows
one of them to establish hydrogen bond with one alcohol function of the
alkyl chain. Two other bonds can be observed with two arginine re-
sidues. The absence of binding with amino acids, positioned deeper
inside the cavity, is in agreement with the SIEFED results, showing a
weak inhibitory effect on the MPO activity.
3.3. Optical measurements- direct action of morphine on the peroxidase
cycle of MPO
Based on a dose-dependent action demonstrated by the ELISA direct
assay, accompanied by the lack of MPO activity inhibition during
SIEFED, we were particularly interested to understand better the me-
chanism of action of morphine towards the peroxidase activity of MPO.
Therefore, we designed a set of experiments using spectroscopic
Fig. 6. The most plausible docking solution of the gallic acid-MPO complex by
GOLD. The yellow dashed lines represent the hydrogen bond between the li-
gand and MPO residue. Selected distances (in Angström) are given on the
scheme.
Fig. 7. The most plausible docking solution of the morphine-MPO complex by
GOLD. The yellow dashed lines represent the hydrogen bond between the li-
gand and MPO residue. Selected distances (in Angström) are given on the
scheme. A and B represent the same solution in two different points of view.
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approach (optical absorption and EPR spectroscopy). For both methods,
we did not investigate the stoichiometric activity of quercetin and gallic
acid. Fig. 9 illustrates the action of morphine, as substrate, on the
peroxidase cycle of MPO triggered by the addition of an excess of H2O2.
The action of ascorbic acid has been compared to the one morphine,
regarding their similar interaction mode with MPO as highlighted by
the SIEFED and the direct analyses.
The spectrum obtained immediately after the addition of H2O2 is
attributed to compound II, characterized by a bathochromic shift of the
Soret band, centered at 455 nm (Fig. 9). The compound I, being ex-
tremely reactive, is rapidly reduced by its interaction with hydrogen
peroxide and is not observed in our conditions. In the absence of a
reducing substrate in solution (Fig. 9A), compound II returns to the
native state by interacting with the superoxide ions generated by the
reduction of compound I. The cycle of MPO continues until the total
consumption of H2O2. [14,54,55] After 3min 30 s, the pursuit of the
absorbance decrease at 455 nm and the increase at 430 nm illustrate the
conversion of compound II into the native enzyme by the interaction
with superoxide ions remaining in solution after the consumption of the
entire H2O2. This transformation, extremely slow in the absence of a
reducing substrate, is characterized by the appearance of an isosbestic
point at 442 nm.
Paumann-Page et al. [14] showed that, in the presence of a 40-fold
excess of H2O2, no more changes in the absorption spectrum were ob-
served after 120min, indicating the end of the enzyme cycle. They have
also demonstrated that the presence of a reducing substrate like as-
corbic acid, accelerates the cycle, particularly the return of compound II
to the native state and thus protects the enzyme against the destructive
action of an excess of hydrogen peroxide [55]. Indeed, H2O2 plays the
role of suicide inhibitor by allowing the formation of compound III. This
compound can then react again with H2O2 to form ROS inside the en-
zyme active site, causing oxidative damages on the heme and amino
acids. The destroyed enzymes do not contribute to the absorption signal
anymore, which explains the loss of the native enzyme Soret peak ab-
sorbance at the end of the enzyme cycle [14].
The results showed in Fig. 9 B, C and D are in accordance with those
reported by Paumann-Page et al. [14]. Even if the measures, realized
over a period of 10min, did not allow to reach the equilibrium state of
MPO in solution, they enable to demonstrate the comparable action of
morphine and ascorbic acid, as reducing substrate in the peroxidase
cycle of MPO.
The measure of the absorbance at 455 nm directly after the trig-
gering of the MPO cycle, in the absence and presence of reducing mo-
lecules, shows that the substrates accelerate the transition of compound
I into compound II. Morphine can get close to the active site of MPO
and interact without inactivating the enzyme. The phenol group of the
molecule is suspected to be responsible for its reducing action, by giving
up an electron to the π-radical state of the enzyme [24]. The use of two
morphine concentrations suggests the dose-dependent action of this
molecule. The first one, 3.5 10−6 M (1 μg/ml), allows to demonstrate
the interaction between a clinical concentration of morphine and the
enzyme. To further investigate morphine action mechanism, a 5
10−5 M concentration has been used.
The return of compound II to the native state, after the total con-
sumption of H2O2, is characterized by the isosbestic point at 442 nm. Its
appearance shows that compound II does not pass through another
intermediate while going back to the native enzyme. Compound III is
not formed anymore. The time interval to achieve the apparition of this
point informs on the cycle run's rate and is of 3min 30 s in the absence
of reducing substrate. The addition of 5 10−5 M of morphine or ascorbic
acid accelerates the total hydrogen peroxide consumption to about
2min.
The two studied molecules protect MPO against the destructive ef-
fect of an excess of H2O2. The increase of the absorbance at 430 nm,
10min after the triggering of the cycle, is about 40% in the presence of
5 10−5 M morphine and about 30% in the presence of similar con-
centration of ascorbic acid versus control without addition of any
substrate. The increase obtained with the clinical concentration of
morphine is lower than 10%. By accelerating the peroxidase cycle of
MPO, morphine and ascorbic acid reduce the ferrous state [14]. In
clinical conditions, the iron released in the extra-cellular medium might
be harmful by producing extremely reactive hydroxyl radicals via a
Fenton-like reaction. Therefore, by protecting MPO, morphine could
have a protective action on the organism.
3.4. EPR measurements - study of the action against the oxidation of ABTS
by the peroxidase cycle of MPO
The efficiency of both morphine and ascorbic acid as substrate, has
been further investigated with EPR. Indeed, the MPO peroxidase cycle
involves radical processes, which can efficiently be studied in EPR
spectroscopy. In the present experiment, the two molecules have been
Fig. 8. The most plausible docking solution of the ascorbic acid-MPO complex by GOLD. The yellow dashed lines represent the hydrogen bond between the ligand
and MPO residue. Selected distances(in Angström) are given on the scheme. A and B represent the same solution in two different points of view.
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studied regarding their protective action on ABTS, a substrate fre-
quently used in enzymatic studies, against its oxidation by the perox-
idase cycle of MPO. Morphine and ascorbic acid, first added in solution
with ABTS before the triggering of the cycle, can compete with the
ABTS molecules to interact with compounds I and II of the enzymes.
Three concentrations (5 10−5 M, 10−4Mand 5 10−4 M), higher than the
clinical concentration range, allow to further investigate the me-
chanism of action of both molecules.
Morphine presents a dose-dependent reducing action on the per-
oxidase cycle of MPO, with an inhibition of the ABTS.+ formation from
about 20% at 5 10−5 M to 85% at 5 10−4 M (Fig. 10). In accordance
with the SIEFED results, ascorbic acid is a more efficient substrate than
morphine with at least 80% of inhibition at the three concentrations.
The hydroxyl groups are proven, for ascorbic acid, to be at the
origin of its antioxidant activity. The association of the reducing and
the low anti-catalytic actions can explain the stronger inhibition of the
ABTS.+ production by ascorbic acid. Indeed, ascorbic acid, is able to get
close not only to the iron atom but also to the most important active site
amino acids, which are essential to trigger the peroxidase cycle by the
natural substrate H2O2. At this position, ascorbic acid is able to transfer
an electron to oxidant compound I or II. Moreover, at high concentra-
tions, from 5 10−5 M, ascorbic acid presents an un-negligible anti-cat-
alytic action (Fig. 3). The stoichiometric inhibition of the ABTS oxi-
dation, clearly demonstrated the ability of morphine to interact with
MPO and therefore, to compete with ABTS when reacting as reducing
substrate. The study of Borges et al. [24] on the redox properties of
Fig. 9. Effect of morphine and ascorbic acid on the transition of compound I of MPO to compound II. A: the peroxidase cycle is initiated by adding H2O2 (3.4 10−4 M)
to a solution containing 9.5 10−7 M MPO. B: the peroxidase cycle is initiated by adding H2O2 (3.4 10−4 M) to a solution containing 9.5 10−7 M MPO and 3.5 10−6 M
morphine. C: the peroxidase cycle is initiated by adding H2O2(3.4 10−4 M) to a solution containing 9.5 10−7 M MPO and 5.5 10−5 M morphine. D: the peroxidase
cycle is initiated by adding H2O2(3.4 10−4 M) to a solution containing 9.5 10−7 M MPO and 5.5 10−5 M ascorbic acid.
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morphine, indicates that the presence of a phenol group may be at the
origin of this antioxidant property, based on its high hydrogen transfer
capacity. Furthermore, our results indicate that the higher the con-
centration in solution, the bigger the steric effects preventing ABTS to
be oxidized by the enzyme. This latter observation brings additional
explanation to the strong inhibition of the ABTS.+ formation seen at the
concentration of 5 10−4 M.
4. Conclusion
Morphine is an opioid analgesic commonly used in clinical practice.
Recent investigations have pointed to non-analgesic effects of morphine
involving antioxidant action and inhibition of several components of
the immune system. MPO, a pivotal enzyme of the oxidative response of
polymorphonuclear neutrophils is a potential target of morphine side
effects. In this study, we characterized the physicochemical features of
morphine-MPO interactions at the light of efficient investigation tools.
We demonstrated that morphine has a direct action on MPO, especially
on its peroxidase cycle. However, the anti-catalytic effect of morphine
is weak and reversible due to its 3D structure leading to steric con-
straints avoiding efficient entering and binding in the active site of
MPO. Nevertheless, since these effects may occur at therapeutic re-
levant concentrations, we raise the possibility that morphine effects on
MPO contribute to immunomodulatory and antioxidant effects of the
opioid during clinical use. However, a further study is needed to de-
termine the inhibition constant and characterize the potential
competitive inhibition mechanism of morphine on MPO. Likewise, to
deepen the study of the activity of morphine in a clinical point of view,
the inhibitory action of its hepatic metabolites, morphine-3-glucuronide
and morphine-6-glucuronide, has been investigated thanks to docking.
Based on these interesting preliminary results, another set of experi-
ments will be performed using the SIEFED and the spectroscopic tech-
niques.
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